Geode Capital Management LLC recently announced the acquisition of new stake in Gain Therapeutics Inc. (NASDAQ:GANX). The institutional investor has increased its shareholding in the Healthcare company by 240.72% to 87967.0 shares with purchase of 62149.0 shares. This fresh investment now brings its stake to 0.74% valued currently at $0.28 million. In addition, Renaissance Technologies LLC raised its holdings by 300.0 to 33400.0 shares.
With over 91779.0 Gain Therapeutics Inc. (GANX) shares trading Tuesday and a closing price of $4.25 on the day, the dollar volume was approximately $0.39 million. The shares have shown a positive half year performance of 4.68% and its price on 01/24/23 gained nearly 3.66%. Currently, there are 11.88M common shares owned by the public and among those 8.99M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for GANX have a consensus price objective of $8.50. The analysts have set the share’s price value over the next 12 months at a high of $10.00 and a low of $4.00. The average price target is 50.0% above its recent price level and a downside to the estimated low will see the stock lose -6.25% over that period. But an upside of 57.5% will see the stock hit the forecast high price target while median target price for the stock is $10.00.
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 18,738 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Gain Therapeutics Inc. are Fidelity Extended Market Index Fu, Bridgeway Ultra Small Company Mar, and Fidelity Total Market Index Fund. Fidelity Extended Market Index Fu owns 46877.0 shares of the company’s stock, all valued at over $0.15 million. Fidelity Total Market Index Fund now owns shares totaling to 0.20% of the shares outstanding.
Shares of Gain Therapeutics Inc. (NASDAQ: GANX) opened at $4.05, down -$0.05 from a prior closing price of $4.10. However, the script later moved the day high at 4.3199, up 3.66%. The company’s stock has a 5-day price change of 13.03% and 37.10% over the past three months. GANX shares are trading 35.78% year to date (YTD), with the 12-month market performance down to -2.75% lower. It has a 12-month low price of $2.33 and touched a high of $6.70 over the same period. GANX has an average intraday trading volume of 35.36K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 24.54%, 31.83%, and 23.51% respectively.
Institutional ownership of Gain Therapeutics Inc. (NASDAQ: GANX) shares accounts for 10.20% of the company’s 11.88M shares outstanding. Mutual fund holders own 2.03%, while other institutional holders and individual stakeholders account for 8.77% and 1.39% respectively.
It has a market capitalization of $48.96M. The earnings-per-share (ttm) stands at -$1.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.72% over the week and 6.30% over the month.
Analysts forecast that Gain Therapeutics Inc. (GANX) will achieve an EPS of -$0.46 for the current quarter, -$0.41 for the next quarter and -$1.56 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.54 while analysts give the company a high EPS estimate of -$0.39. Comparatively, EPS for the current quarter was -$0.39 a year ago. Earnings per share for the fiscal year are expected to decrease by -332.80%, and 13.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Gain Therapeutics Inc. (GANX) as a “Strong Buy” at a consensus score of 1.50. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the GANX, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on April 12, 2021, with the firm’s price target at $30. BTIG Research coverage for the Gain Therapeutics Inc. (GANX) stock in a research note released on April 12, 2021 offered a Buy rating with a price target of $30.